Quotient featured in Drug Development & Delivery's Outsourcing Formulation Development & Manufacturing Special Feature
Quotient's VP of Drug Development Sciences, Dr Sarah Stevens, discusses our recent acquisition of Arcinova and the integration of drug substance, drug product, and clinical testing capabilities – all under one organization, in Drug Development & Delivery's Special Feature Report
Quotient Sciences wins multiple categories in 2021 CRO Leadership Awards
Content: Quotient has been recognized with multiple 2021 CRO Leadership Awards, including two Champion Awards. The CRO Leadership Awards recognizes top performing outsourcing organizations in the drug development arena. Quotient received leadership awards in five of the overall six categories.
Quotient featured in Drug Development & Delivery's Solubility Special Feature Report
Quotient Sciences was featured in Drug Development & Delivery's Special Feature article entitled: "Improving Bioavailability & Solubility: Each Molecule Is Unique."
Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization
Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.
Arcinova announces major investment in Alnwick site with the installation of the R1000 capsule fill machine from 3P Innovation
Arcinova, a Quotient Sciences business, announces major investment in Alnwick site with the installation of the R1000 capsule fill machine from 3P Innovation